For the roughly 80 million people worldwide living with glaucoma, daily life often means watching the world slowly close in. Peripheral vision fades first, so gradually that many people do not notice until significant damage is done. Reading a book, driving at night, or recognizing a face in a crowd becomes harder, then impossible in the affected areas. For those with non-arteritic anterior ischemic optic neuropathy (NAION), the onset is more sudden: patients typically wake up one morning to find a patch of vision in one eye simply gone, with no pain to explain it and no approved treatment to bring it back.
Treatment for glaucoma today boils down to one strategy: slow the damage. Eye drops, laser procedures, and surgery can lower pressure inside the eye, but none can undo the harm already done to the optic nerve. Once those nerve cells deteriorate, the vision they carried is gone.
A small clinical trial now cleared to begin in the United States is asking whether that rule can be broken. Life Biosciences, a biotechnology company focused on cellular aging, received FDA clearance on January 28, 2026, to launch the first human trial of ER-100, a gene therapy designed to reverse aging at the cellular level in the eye. It is the first time partial epigenetic reprogramming, a technique that resets age-related changes in a cell’s gene activity, will be tested in people.
From aged mice to human eyes
The scientific roots of ER-100 trace back to a landmark 2020 study published in Nature by researchers at Harvard Medical School. That team, led by Yuancheng Lu and David Sinclair, showed that delivering three specific genes, known as OCT4, SOX2, and KLF4 (the OSK factors), could restore vision in aged mice by reprogramming retinal ganglion cells to a younger state. The cells regained function without losing their specialized identity, a critical distinction from full reprogramming, which converts mature cells all the way back into stem cells and carries serious risks, including tumor formation.
ER-100 builds on that foundation. The therapy uses an adeno-associated virus (AAV), a well-established delivery vehicle in gene therapy, to carry the OSK factors directly into optic nerve tissue. The goal is partial reprogramming: dialing back the epigenetic clock on damaged nerve cells just enough to restore some function, without erasing what makes them nerve cells in the first place.
The Phase 1 trial, registered on ClinicalTrials.gov under identifier NCT07290244, will enroll two groups of adults: those with open-angle glaucoma (OAG), the most common form of the disease, and those with NAION. Both conditions cause progressive, irreversible vision loss driven by optic nerve degeneration.
What the trial will and will not measure
This is a safety study, not an efficacy trial. The primary endpoints are adverse events and immune responses, the standard benchmarks for any first-in-human gene therapy. Investigators may collect exploratory data on visual function or structural changes in the optic nerve, but those observations are secondary. The trial is designed to answer one question first: is ER-100 safe to put into a human eye?
The eye offers certain advantages as a testing ground. It is a small, enclosed space, which limits the dose of virus needed and makes it easier to monitor. It also benefits from partial immune privilege, a biological feature that dampens inflammatory responses to foreign material. That property could reduce the risk of severe immune reactions to the AAV vector, though “could” is doing real work in that sentence. No one has delivered OSK factors to human optic nerve tissue before, and the immune dynamics in a diseased eye may differ from those in a healthy one.
Independent reporting in Nature Biotechnology confirmed the FDA clearance and described ER-100’s mechanism, providing a third-party check on the company’s own announcement. That coverage aligns with both the press release and the trial registry on all material points.
What we do not know yet
The verified facts are narrow. Life Biosciences has not publicly released detailed preclinical data for ER-100, such as the degree of vision restoration observed in animal models, how long the reprogramming effect lasted, or what doses were tested. The Nature Biotechnology article references animal model work in general terms, but specific quantified results from those studies have not appeared in any publicly available document reviewed here. Without that information, outside scientists cannot independently evaluate how strong the case for moving to humans actually is.
The FDA’s clearance of the investigational new drug (IND) application means the agency found no grounds to block the trial on safety concerns. It is a regulatory green light to proceed with testing, not a vote of confidence in the therapy’s effectiveness. The agency has not released review documents or public commentary on ER-100, which is standard practice for IND clearances.
Practical details remain sparse as well. The trial registry confirms the study design and target populations but does not specify enrollment targets, the number of clinical sites, recruitment timelines, or when the first patients will receive a dose. Those details typically emerge after a trial opens to enrollment.
A deeper scientific uncertainty involves control. Partial reprogramming depends on activating OSK factors at just the right intensity and duration. In broader animal research on reprogramming, overexpression or prolonged activation of similar factors has sometimes triggered unwanted outcomes, including loss of cell specialization or tumor growth. The publicly available documents do not describe the regulatory mechanism ER-100 uses to govern OSK activity in human tissue, leaving a gap in understanding how the company plans to manage that balance.
A crowded and well-funded field
ER-100 is not the only bet being placed on cellular reprogramming. Altos Labs, backed by more than $3 billion in funding, is pursuing reprogramming research across multiple tissue types. Retro Biosciences, funded in part by Sam Altman, is exploring partial reprogramming as a path to extending human healthspan. But none of these competitors have reached a cleared human trial for epigenetic reprogramming as of spring 2026, which makes the ER-100 study a genuine first in the field.
The distinction matters because the entire field has operated, until now, on animal data and theoretical promise. A human safety study, even a small Phase 1, will generate the first real-world evidence about how reprogramming factors behave in living human tissue. If the immune and safety profile proves manageable in the eye, the results could open the door to trials targeting other parts of the nervous system or other age-related diseases. If serious problems emerge, they will force a recalibration of timelines across the sector.
What this means for patients watching the trial registry
For people living with glaucoma or NAION, ER-100 is an experimental option, not a treatment. The Phase 1 design means a small number of patients will be enrolled, and the study is built to assess safety rather than to demonstrate clinical benefit. Anyone interested in participating should monitor the trial registry for enrollment updates and discuss eligibility and risks with their ophthalmologist.
The odds are long. Most gene therapies that enter Phase 1 trials never reach the market. Some fail on safety; others prove safe but do not deliver enough benefit to justify continued development. Broad industry analyses of drug development attrition, such as those published by the Biotechnology Innovation Organization (BIO), consistently show that fewer than 10% of drugs entering Phase 1 ultimately win FDA approval.
Still, the clearance of ER-100 marks a tangible shift. For years, the idea that aging could be reversed at the cellular level lived in academic papers and investor pitch decks. As of late January 2026, it lives in a registered clinical trial with real patients, real endpoints, and a regulatory framework that will force the data into the open. Whether that data validates the promise or exposes its limits, the answer will come from human evidence, and that process has now officially begun.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
